Which of the following cytogenetic abnormalities places a patient with de novo AML in the favourable-risk category of the European LeukaemiaNet stratification?
- A inv(3)(q21q26.2)
- B t(9;22)(q34;q11.2), BCR-ABL1
- C t(8;21)(q22;q22), RUNX1-RUNX1T1 ✓
- D Monosomal karyotype
Correct answer: C. t(8;21)(q22;q22), RUNX1-RUNX1T1
Explanation
The European LeukaemiaNet system assigns t(8;21) RUNX1-RUNX1T1, inv(16) CBFB-MYH11 and mutated NPM1 without FLT3-ITD to the favourable group. These core binding factor leukaemias respond well to anthracycline induction followed by high-dose cytarabine consolidation. t(9;22) in AML, inv(3) and monosomal karyotype are all adverse-risk lesions and predict poor response to standard therapy.
Reference: Robbins and Cotran Pathologic Basis of Disease, 10th ed.
High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP
Written and medically reviewed by the StethoPrep medical team.